Two drug candidates failed to overturn negative opinions on reexamination, as the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) reaffirmed refusals for KemSu (sufentanil-ketamine, Proveca Pharma Limited) for acute pain in children and adolescents and Meplyffa (arimoclomol citrate, Zevra Denmark A/S) for Niemann-Pick disease type C (NPC).Both outcomes followed reexaminations requested by the companies after initial negative opinions on July 23, 2026. KemSu KemSu was developed for acute pain in children aged 1 to less than 18 years. It is a fixed-dose nasal spray to be given by a healthcare professional experienced in pain management, in a setting with resuscitation equipment and patient monitoring. Sufentanil is a mu-opioid receptor agonist, and ketamine acts at NMDA receptors.The company provided results from a main study evaluating whether sufentanil-ketamine could reduce acute pain in children and adolescents. In a phase 3 study, 155 children presenting to the emergency department with injury-related moderate-to-severe pain received the combination, with a second dose permitted 10-15 minutes later if pain relief was insufficient. The primary endpoint was the proportion of children with a pain score of 4 or below, measured twice in the 30 minutes after the first dose.Supportive data came from a study of 220 adults undergoing impacted mandibular third molar extraction. Participants received the combination, intranasal sufentanil alone, intranasal ketamine alone, or placebo. The primary measure was overall pain reduction during the first 55 minutes.The CHMP concluded that the superiority of the combination over sufentanil alone could not be confirmed. The pediatric study showed pain reduction but had no comparator, and the adult study found the combination no more effective than sufentanil alone. The company argued that ketamine could reduce opioid-related adverse effects, citing lower sufentanil levels in adults who received the combination. In children, however, sufentanil exposure was model-based rather than measured, and the agency found no evidence that lower exposure would improve safety.The committee also cited product concerns. The device has no lock-out mechanism to prevent repeat use, which carries a risk of accidental overdose, and a significant amount of drug remains in the bottle after use, raising the risk of misuse and diversion.Meplyffa Meplyffa was intended as an oral add-on to miglustat in patients aged 2 years and older with NPC, a progressive genetic disorder of intracellular lipid transport caused by NPC1 or NPC2 mutations. Arimoclomol increases activation of TFEB and TFE3, which was expected to boost production of functional NPC proteins and promote lipid clearance. The drug received EU orphan designation in November 2014. An earlier application, submitted as Miplyffa, was withdrawn in March 2022.The company provided results of a main study that evaluated whether arimoclomol could slow progression of NPC over time. In a phase 2/3 trial, 50 patients aged 2-18 years received arimoclomol or placebo for 12 months, with most participants also receiving miglustat as standard care. The primary endpoint was change in the 5-domain NPC Clinical Severity Scale, which rates ambulation, swallowing, cognition, speech, and fine motor skills. Mean progression was 0.76 with arimoclomol vs 2.15 with placebo, a treatment difference of -1.40.The CHMP, however, raised concerns about data handling and analysis that left the reliability and robustness of the results uncertain. It also noted no benefit in ambulation or cognition. A treatment effect favoring arimoclomol in patients taking miglustat was not considered robust because efficacy was not shown in the overall population.Reexamination For Meplyffa, the CHMP reassessed the data, consulted experts in NPC including patient representatives, and considered input from a patient organization representing patients and caregivers. It acknowledged the unmet medical need but concluded its concerns remained unresolved. In the KemSu reexamination, the committee likewise maintained that the benefit-risk balance was not favorable.Effect on Patients and Next Steps Proveca told the agency that patients in clinical trials with KemSu are not affected. Zevra said it plans to continue its compassionate-use programs for Meplyffa, pending discussions with the national authorities that approved them. The EMA advised patients in trials or compassionate-use programs to speak with their doctors about their treatment.This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
EMA Upholds Refusals for Pediatric Pain Spray and NPC Drug
Full Article
Original Source
Read the full article at Medscape →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.